Innovative Steps in Cancer Treatment: Parabilis Medicines at ASCO
Parabilis Medicines, a clinical-stage biopharmaceutical company, is on the cutting edge of research and development for novel cancer therapies. During the upcoming American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, they will present a trial-in-progress poster detailing their latest findings regarding FOG-001, a groundbreaking ?-cateninTCF4 inhibitor.
Advancing Cancer Treatment with FOG-001
FOG-001 is leading the way in clinical trials, specifically designed for patients with difficult-to-treat solid tumors, such as microsatellite stable colorectal cancer (MSS CRC). This first-in-human clinical trial explores the safety and efficacy of FOG-001, the first direct inhibitor of the ?-catenin/TCF4 protein interactions. By inhibiting this pathway, the hope is to provide new treatment options for patients who currently have limited available therapies.
Key Features of the Trial
The Phase 1/2 trial, an open-label and multicenter study, aims to evaluate various key aspects of FOG-001, namely its safety, tolerability, pharmacokinetics, pharmacodynamics, and potential antitumor activity. The trial is particularly focused on patients who have experienced specific genetic mutations associated with the Wnt signaling pathway, which is known to drive cancer progression.
Clinical Progress and Insights
At a recent healthcare conference, the company shared updates, revealing that over 60 patients have already received FOG-001. Early indications suggest that this therapy is showing promise in terms of antitumor activity and target engagement within tumors. Initial data from this research is anticipated to be publicly available within the next year, which could offer new hope for patients battling colorectal cancer and other solid tumor types.
Poster Presentation Details at ASCO 2025
During the symposium, Parabilis will present crucial data that underline the potential of FOG-001:
Title: “A Phase 1/2 study of FOG-001, a first-in-class direct ?-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors”
Abstract Number: TPS322
Presentation Date and Time: January 25, 2025, from 7:00 to 7:55 a.m. PST
Session Information: Trials in Progress Poster Session C
Location: Level 1, West Hall, Moscone West
Understanding FOG-001 and its Mechanism
FOG-001 is designed to be a first-in-class competitive inhibitor targeting the interactions between ?-catenin and TCF transcription factors. This unique approach aims to circumvent the common mutations associated with cancer, which can often complicate treatment. By interrupting the Wnt signaling pathway, FOG-001 presents a novel avenue for combating cancer growth at a cellular level.
How FOG-001 Operates
The innovative design of FOG-001 allows it to bind directly within the cancer cells, disrupting the pivotal oncogenic activities of ?-catenin. This targeted action differentiates FOG-001 from other therapies by acting at an essential point of the signaling cascade that is crucial for tumor development.
About Parabilis Medicines
Parabilis Medicines, formerly known as Fog Pharmaceuticals, is deeply committed to finding extraordinary solutions for cancer care. Their Helicon discovery platform is pivotal in creating precise, stabilized helical peptide therapeutics that can address numerous traditionally hard-to-treat targets. The company’s pipeline aims to explore this versatile technology across several therapeutic domains, including targeted protein degraders and radiopharmaceuticals.
Headquartered in Cambridge, Mass., Parabilis has successfully raised over $500 million from leading life sciences investors to advance its research and clinical trials, solidifying its position at the forefront of cancer therapy development.
Frequently Asked Questions
What is FOG-001?
FOG-001 is a first-in-class ?-catenin/TCF4 inhibitor currently undergoing clinical trials aimed at treating various solid tumors, particularly colorectal cancer.
What are the goals of the trial?
The trial primarily seeks to assess the safety, tolerability, pharmacokinetics, and antitumor effects of FOG-001 in patients facing advanced solid tumors.
How many patients are involved in the trial?
Currently, over 60 patients with locally advanced or metastatic tumors have been dosed with FOG-001 as part of the clinical trial.
When will the results of the trial be shared?
Initial data from the trial is expected to be disclosed in 2025, offering insights into the efficacy of FOG-001.
Where can I find more information about Parabilis Medicines?
Further details about the company and its trials can be found on their official website.
